Get to know our clinical trials
Phase II/III, multicenter, randomized, double-blind clinical trial of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for the first-line treatment of PD-L1-positive squamous cell carcinoma of the head and neck.
LA FINALIDAD PRINCIPAL DE ESTE ESTUDIO ES INVESTIGAR EL FÁRMACO DEL ESTUDIO EN COMBINACIÓN CON PEMBROLIZUMAB. SE ESTUDIARÁ SU SEGURIDAD, LA FORMA EN QUE EL ORGANISMO ABSORBE, DISTRIBUYE Y ELIMINA EL FÁRMACO DEL ESTUDIO, CÓMO ACTÚA EL FÁRMACO DEL ESTUDIO EN EL ORGANISMO Y SI FUNCIONA PARA TRATAR EL CÁNCER QUE PADECE.
Technical Summary
- PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF FICERAFUSP ALFA (BCA101) OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PD-L1-POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA.
- Code EudraCT: 2024-519654-37
- Protocol number: BCA101X301
- Promoter: Biofabri
- Molecule/Drug: BCA101 (Ficerafusp alfa) - Pembrolizumab
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.